• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

REGENXBIO (RGNX)

Common Shares
Sell: $8.50|Buy: $8.80|Change: 0.10 (-1.16%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeuticproteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.

Address

9600 Blackwell Road
Suite 210
Rockville
MD
USA
20850

Telephone

+1 240 5528181

Website

https://www.regenxbio.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Regenxbio Inc Fourth Quarter Earnings Conference Call for 20262027-03-05T08:00:00
Regenxbio Inc Fourth Quarter Earnings Results for 20262027-03-05T00:00:00
Regenxbio Inc Annual Report for 20262027-03-05T00:00:00
Regenxbio Inc Third Quarter Earnings Conference Call for 20262026-11-06T08:00:00
Regenxbio Inc Third Quarter Earnings Results for 20262026-11-06T00:00:00
Regenxbio Inc Second Quarter Earnings Conference Call for 20262026-08-07T08:00:00
Regenxbio Inc Second Quarter Earnings Results for 20262026-08-07T00:00:00
Regenxbio Inc Annual General Meeting for 20262026-05-29T09:00:00
Regenxbio Inc First Quarter Earnings Conference Call for 20262026-05-12T16:30:00
Regenxbio Inc First Quarter Earnings Results for 20262026-05-12T00:00:00

Previous key dates

NameKey Date
RBC Inaugural Virtual Ophthalmology Conference2026-03-24T08:45:00
Leerink Global Healthcare Conference2026-03-09T09:20:00
Regenxbio Inc Fourth Quarter Earnings Conference Call for 20252026-03-05T08:00:00
Regenxbio Inc Fourth Quarter Earnings Result for 20252026-03-05T00:00:00
Regenxbio Inc Annual Report for 20252026-03-05T00:00:00
44th Annual J.P. Morgan Healthcare Conference2026-01-14T10:30:00
Piper Sandler 37th Annual Healthcare Conference2025-12-02T08:30:00
Stifel 2025 Healthcare Conference2025-11-11T13:20:00
Guggenheim Securities 2nd Annual Healthcare Innovation Conference2025-11-10T09:00:00
Regenxbio Inc Third Quarter Earnings Conference Call for 20252025-11-06T08:00:00
Regenxbio Inc Third Quarter Earnings Result for 20252025-11-06T00:00:00
H.C. Wainwright 27th Annual Global Investment Conference2025-09-09T14:30:00
Baird 2025 Global Healthcare Conference2025-09-09T08:30:00
Morgan Stanley 23rd Annual Global Healthcare Conference2025-09-08T11:30:00
Regenxbio Inc Second Quarter Earnings Conference Call for 20252025-08-07T08:00:00
Regenxbio Inc Second Quarter Earnings Result for 20252025-08-07T00:00:00
AFFINITY DUCHENNE® Trial of RGX-202: Phase I/II Interim Functional Data2025-06-05T08:00:00
Regenxbio Inc Annual General Meeting for 20252025-05-30T09:00:00
RBC Global Healthcare Conference2025-05-20T11:30:00
BofA Securities Health Care Conference 20252025-05-13T17:00:00
Regenxbio Inc First Quarter Earnings Conference Call for 20252025-05-12T16:30:00
Regenxbio Inc First Quarter Earnings Results for 20252025-05-12T00:00:00
RBC Inaugural Virtual Ophthalmology Conference2025-04-03T08:15:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.